FIGS Stock Analysis: Figs | NYSE
Apparel Manufacturing | NYSE, USA | Market Cap: 2.622m USD | 12M Return: 150.2% | US30260D1037 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 37.9M
EPS Trend: 23.6%
Qual. Beats: 1
Rev. Trend: 86.4%
Qual. Beats: 1
Warnings
Tailwinds
Seasonality 5.3 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
FIGS, Inc. is a direct-to-consumer healthcare apparel and lifestyle company headquartered in Santa Monica, California, founded in 2013. The company designs, markets, and sells scrubwear and a range of non-scrubwear products-including outerwear, underscrubs, footwear, compression socks, lab coats, loungewear, and accessories such as scrub caps, lanyards, and bags-to healthcare professionals primarily in the United States, with international operations through its Canadian subsidiary.
Sales are generated through a multi-channel model combining a digital DTC platform (website and mobile app), a B2B segment serving institutional buyers, and physical retail stores. The company operates within the GICS Health Care Supplies sub-industry, carving out a branded niche in the historically fragmented medical apparel market by targeting individual healthcare workers rather than relying solely on traditional wholesale hospital supply channels.
- Gross margin compresses on promotions and higher input costs
- DTC digital sales growth slows as competition intensifies
- International and B2B expansion provides incremental growth offset
| Net Income: 61.9m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.17 > 0.02 and ΔFCF/TA 8.97 > 1.0 |
| NWC/Revenue: 50.92% < 20% (prev 55.35%; Δ -4.43% < -1%) |
| CFO/TA 0.19 > 3% & CFO 108.0m > Net Income 61.9m |
| Net Debt (-238.6m) to EBITDA (87.3m): -2.73 < 3 |
| Current Ratio: 4.96 > 1.5 & < 3 |
| Outstanding Shares: last quarter (195.1m) vs 12m ago 12.84% < -2% |
| Gross Margin: 68.43% > 18% (prev 67.23%; Δ 1.20% > 0.5%) |
| Asset Turnover: 129.1% > 50% (prev 110.1%; Δ 18.98% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.62 (Total Current Assets 452.9m - Total Current Liabilities 91.4m) / Total Assets 582.7m |
| B: 0.23 (Retained Earnings 133.4m / Total Assets 582.7m) |
| C: 0.14 (EBIT TTM 76.6m / Avg Total Assets 549.9m) |
| D: 3.15 (Book Value of Equity 442.4m / Total Liabilities 140.3m) |
| Altman-Z'' = 9.06 = AAA |
| DSRI: 2.05 (Receivables 23.3m/9.12m, Revenue 710.1m/569.6m) |
| GMI: 0.98 (GM 67.23% / 68.43%) |
| AQI: 0.91 (AQ_t 0.07 / AQ_t-1 0.08) |
| SGI: 1.25 (Revenue 710.1m / 569.6m) |
| TATA: -0.08 (NI 61.9m - CFO 108.0m) / TA 582.7m) |
| Beneish M = -2.06 (Cap -4..+1) = BB |
As of October 13, 2026, the stock is trading at USD 17.74 with a total of 11,310,247 shares traded. Over the past week, the price has changed by +30.15%, over one month by +26.90%, over three months by +77.40% and over the past year by +150.21%.
Current recommended Stop Loss: 16.40 (which is 7.6% or 1.9 ATR below the current price).
Figs has received a consensus analysts rating of 4.00. Therefore, it is recommended to buy FIGS.
- StrongBuy: 4
- Buy: 1
- Hold: 4
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 18.6 | 5% |
P/E Trailing = 47.8182
P/E Forward = 31.5457
P/S = 3.6921
P/B = 4.4956
Revenue TTM = 710.1m USD
EBIT TTM = 76.6m USD
EBITDA TTM = 87.3m USD
Long Term Debt = 48.7m USD (estimated: total debt 57.7m - short term 9.00m)
Short Term Debt = 9.00m USD (from shortTermDebt, last quarter)
Debt = 57.7m USD (from shortLongTermDebtTotal, last quarter) (leases 57.7m already included)
Net Debt = -238.6m USD (calculated: Debt 57.7m - CCE 296.3m)
Enterprise Value = 2.38b USD (2.62b + Debt 57.7m - CCE 296.3m)
Interest Coverage Ratio = unknown (Ebit TTM 76.6m / Interest Expense TTM 0.0)
EV/FCF = 24.51x (Enterprise Value 2.38b / FCF TTM 97.2m)
FCF Yield = 4.08% (FCF TTM 97.2m / Enterprise Value 2.38b)
FCF Margin = 13.69% (FCF TTM 97.2m / Revenue TTM 710.1m)
Net Margin = 8.72% (Net Income TTM 61.9m / Revenue TTM 710.1m)
Gross Margin = 68.43% ((Revenue TTM 710.1m - Cost of Revenue TTM 224.2m) / Revenue TTM)
Gross Margin QoQ = 75.20% (prev 65.59%)
Tobins Q-Ratio = 4.09 (Enterprise Value 2.38b / Total Assets 582.7m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 57.7m)
Taxrate = 19.20% (14.7m / 76.6m)
NOPAT = 61.9m (EBIT 76.6m * (1 - 19.20%))
Current Ratio = 4.96 (Total Current Assets 452.9m / Total Current Liabilities 91.4m)
Debt / Equity = 0.13 (Debt 57.7m / totalStockholderEquity, last quarter 442.4m)
Debt / EBITDA = -2.73 (Net Debt -238.6m / EBITDA 87.3m)
Debt / FCF = -2.45 (Net Debt -238.6m / FCF TTM 97.2m)
Total Stockholder Equity = 430.9m (last 4 quarters mean from totalStockholderEquity)
RoA = 11.26% (Net Income 61.9m / Total Assets 582.7m)
RoE = 14.37% (Net Income TTM 61.9m / Total Stockholder Equity 430.9m)
RoCE = 15.98% (EBIT 76.6m / Capital Employed (Equity 430.9m + L.T.Debt 48.7m))
RoIC = 13.32% (NOPAT 61.9m / Invested Capital 464.8m)
WACC = 7.76% (E(2.62b)/V(2.68b) * Re(7.93%) + D(57.7m)/V(2.68b) * Rd(0.0%) * (1-Tc(0.19)))
Discount Rate = 7.93% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 61.63 | Cagr: 3.48%
[DCF] Terminal Value 77.97% ; FCFF base≈74.3m ; Y1≈85.2m ; Y5≈125.3m
[DCF] Fair Price = 13.46 (EV 1.89b - Net Debt -238.6m = Equity 2.12b / Shares 157.9m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 23.61 | EPS CAGR: 29.82% | SUE: 1.29 | # QB: 1
Revenue Correlation: 86.40 | Revenue CAGR: 8.93% | SUE: 0.89 | # QB: 1
EPS current Quarter (2026-09-30): EPS=0.07 | Chg30d=-2.29% | Revisions=-25% | Analysts=6
EPS current Year (2026-12-31): EPS=0.36 | Chg30d=+1.58% | Revisions=-25% | GrowthEPS=+90.0% | GrowthRev=+20.6%
EPS next Year (2027-12-31): EPS=0.38 | Chg30d=+2.75% | Revisions=-25% | GrowthEPS=+5.6% | GrowthRev=+9.2%
[Analyst] Revisions Ratio: -50% (up=0, down=3)